Lmr Partners LLP Altimmune, Inc. Transaction History

Lmr Partners LLP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$2.14 - $11.62 $41,747 - $226,682	-19,508 Reduced 43.83%	25,000 $281,000
Q3 2023 Nov 14, 2023	BUY	$2.4 - $3.45 $106,819 - $153,552	44,508 New	44,508 $115,000
Q1 2023 May 15, 2023	BUY	$4.19 - $16.83 $322,529 - $1.3 Million	76,976 New	76,976 $324,000
Q2 2022 Aug 15, 2022	BUY	$3.94 - $11.77 $55,707 - $166,416	14,139 New	14,139 $165,000
Q1 2022 May 16, 2022	SELL	$5.9 - $9.45 $118,000 - $189,000	-20,000 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$8.69 - $12.48 $175,963 - $252,707	-20,249 Reduced 50.31%	20,000 $183,000
Q3 2021 Nov 15, 2021	BUY	$8.43 - $16.81 $339,299 - $676,585	40,249 New	40,249 $455,000
Q2 2021 Aug 16, 2021	SELL	$9.85 - $16.46 $209,982 - $350,894	-21,318 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$12.71 - $24.31 $270,951 - $518,240	21,318 New	21,318 $301,000

186

39.3M

913K

743K

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $404M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of Lmr Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Lmr Partners LLP with notifications on news.